News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
682,990 Results
Type
Article (38959)
Company Profile (276)
Press Release (643755)
Section
Business (203817)
Career Advice (1985)
Deals (35356)
Drug Delivery (84)
Drug Development (80765)
Employer Resources (168)
FDA (16084)
Job Trends (14796)
News (344455)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1212)
Approvals (16002)
Artificial intelligence (114)
Bankruptcy (352)
Best Places to Work (11458)
Biotechnology (196)
Breast cancer (101)
Cancer (886)
Cardiovascular disease (76)
Career advice (1656)
Cell therapy (193)
Clinical research (63887)
Collaboration (317)
Compensation (158)
COVID-19 (2520)
Cystic fibrosis (78)
Data (829)
Diabetes (128)
Diagnostics (6090)
Earnings (84091)
Employer resources (146)
Events (108757)
Executive appointments (239)
FDA (16514)
Funding (286)
Gene therapy (146)
GLP-1 (554)
Government (4316)
Healthcare (18649)
Infectious disease (2593)
Inflammatory bowel disease (101)
Interviews (308)
IPO (16263)
Job creations (3622)
Job search strategy (1415)
Layoffs (407)
Legal (7847)
Lung cancer (154)
Manufacturing (148)
Medical device (13140)
Medtech (13145)
Mergers & acquisitions (19100)
Metabolic disorders (348)
Neuroscience (1450)
NextGen Class of 2024 (6493)
Non-profit (4462)
Northern California (1177)
Obesity (209)
Opinion (175)
Patents (94)
People (56104)
Phase I (19814)
Phase II (28128)
Phase III (21007)
Pipeline (202)
Postmarket research (2553)
Preclinical (8422)
Radiopharmaceuticals (234)
Rare diseases (178)
Real estate (5888)
Regulatory (21425)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1062)
Startups (3560)
United States (11422)
Vaccines (533)
Weight loss (156)
Date
Last 7 days (773)
Last 30 days (2642)
Last 365 days (35549)
2024 (30096)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (186)
Asia (36999)
Australia (6034)
California (2665)
Canada (1163)
China (207)
Colorado (115)
Connecticut (117)
Europe (79193)
Florida (385)
Georgia (98)
Illinois (306)
Indiana (175)
Kansas (95)
Maryland (507)
Massachusetts (2165)
Michigan (142)
Minnesota (246)
New Jersey (805)
New York (824)
North Carolina (656)
Northern California (1177)
Ohio (123)
Pennsylvania (737)
South America (1091)
Southern California (1062)
Texas (372)
Utah (77)
Washington State (315)
682,990 Results for "gradalis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lone Star Bio
Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas
Gradalis, Inc. announced that it has been awarded a $9.9 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas.
November 16, 2023
·
9 min read
Lone Star Bio
Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment
Gradalis, Inc. announced a peer-reviewed publication in Cancers, highlighting the newly discovered critical clinical role of clonal neoantigens in the durable efficacy of immunotherapies in oncology and the potential to use clonal neoantigens as a new biomarker to better identify patients who will best respond to certain immunotherapies.
December 5, 2023
·
12 min read
Lone Star Bio
Gradalis to Participate in the Cantor Global Healthcare Conference
Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the Cantor Global Healthcare Conference, being held in New York, NY from September 26-28, 2023.
September 21, 2023
·
4 min read
Lone Star Bio
Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers
Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, announced GRAD1405 has demonstrated robust, dose-related tumor growth control.
January 4, 2024
·
7 min read
Lone Star Bio
Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
Gradalis, Inc. announced the peer-reviewed publication in Oncology Reviews, a Frontiers Open Access Journal, highlighting Vigil activity in ovarian cancer related to clonal neoantigen expression and the HRP molecular profile.
September 28, 2023
·
7 min read
Lone Star Bio
Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer on October 25, 2023
Gradalis, Inc. announced that it will host a virtual KOL discussion on the Vigil® platform entering Phase 2 for platinum-sensitive recurrent ovarian cancer on Wednesday, October 25, 2023 at 11:00am ET.
October 18, 2023
·
7 min read
Business
Solve GNE and Gradalis Sign Agreement to Develop a Novel Gene Therapy Targeting HIBM
Solve GNE announced today that it has entered into a sponsored research agreement with Gradalis, Inc. to provide funding for a novel lipid nanoparticle gene therapy aimed at curing GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM).
July 31, 2023
·
5 min read
Lone Star Bio
Gradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium
Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023.
March 29, 2023
·
3 min read
Lone Star Bio
Gradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil Platform
Gradalis Inc. announced the peer-reviewed publication in Advanced NanoBioMed, highlighting the therapeutic applications of a new extracellular matrix platform developed for tumor cell expansion in collaboration with the University of Michigan Biointerfaces Institute.
June 6, 2023
·
7 min read
Lone Star Bio
Gradalis to Present at the 2023 BIO CEO & Investor Conference
Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will provide a corporate update at the BIO CEO & Investor Conference being held both virtually and in New York, NY on February 6-9, 2023.
February 2, 2023
·
3 min read
1 of 68,299
Next